Skip to Content
Apply Now

Therapeutics

Revance’s therapeutic pipeline aims to revolutionize how neuromodulators are used to treat muscle movement, neurological, and musculoskeletal conditions.

Therapeutics: Facts, Figures, & Trends

image description
$2.5 billion

Estimated global sales of neuromodulators for therapeutic use.1

image description
10+

Approved indications for botulinum toxin type A.2

image description
3

Ongoing clinical trials for therapeutic indications of DaxibotulinumtioxinA for Injection 3,4,5

  • PRECLINICAL
  • PHASE 1
  • PHASE 2
  • PHASE 3

DaxibotulinumtoxinA for Injection — Therapeutics

Cervical Dystonia
PHASE 3 COMPLETE
Upper Limb Spasticity
IN PHASE 2
Plantar Fasciitis
IN PHASE 2
Migraine
IN PRECLINICAL
Multiple Data Readouts in 2020
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
  • PHASE 3

DaxibotulinumtoxinA for Injection — Therapeutics

Cervical Dystonia
PHASE 3 COMPLETE
Upper Limb Spasticity
IN PHASE 2
Plantar Fasciitis
IN PHASE 2
Migraine
IN PRECLINICAL
Multiple Data Readouts in 2020

Daring to Make a Difference in Therapeutics

Revance is currently enrolling patients in three clinical programs evaluating DaxibotulinumtoxinA for Injection in therapeutic indications. These include: cervical dystonia (Phase 3), upper limb spasticity (Phase 2), and plantar fasciitis (Phase 2). The topline results are anticipated in the first half of 2020 for cervical dystonia and plantar fasciitis trials. Revance is also investigating the use of DaxibotulinumtoxinA for Injection for migraine.

For the latest information regarding our clinical development programs, please see our public filings with Securities and Exchange Commissions or visit www.clinicaltrials.gov.

Publications

DaxibotulinumtoxinA for Injection is an investigational product. It is currently undergoing clinical studies for both therapeutic and aesthetic indications.

Clinical Information
image description

Careers with Revance

Do you have what it takes to join our team? Check out our Careers page and find out.

Careers

References

  1. Based on 2018 estimates from Global Industry Analysts, Inc. Botulinum Toxin – A Global Strategic Business Report, January 2018, UBS
    Specialty Pharmaceuticals Handbook April 2018 and Allergan 2018 Financials
  2. XEOMIN (incobotulinumtoxinA) Prescribing Information. Merz Pharmaceuticals, May 2019.
    DYSPORT® (abobotulinumtoxinA) Prescribing Information. Ipsen Biopharmaceuticals, January 2019.
    BOTOX (onabotulinumtoxinA) Prescribing Information. Allergan, June 2019.
  3. Clinicaltrials.gov. US National Library of Medicine. Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult
    Upper Limb Spasticity (JUNIPER). Available at: https://clinicaltrials.gov/ct2/show/NCT03821402. Accessed July 2019.
  4. Clinicaltrials.gov. US National Library of Medicine. Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated
    Cervical Dystonia (ASPEN-1) (ASPEN-1) Available at: https://clinicaltrials.gov/ct2/show/NCT03608397. Accessed July 2019.
  5. Clinicaltrials.gov. US National Library of Medicine. DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis.
    Available at: https://clinicaltrials.gov/ct2/show/NCT03825315. Accessed July 2019.
Back to top